# Optimization and Validation of Minimally-Invasive and Low-Cost Blood Collection Device for Lead Testing

> **NIH NIH R41** · SKYWAY BIOSCIENCES · 2024 · $295,923

## Abstract

SUMMARY
Lead (Pb) poisoning remains a global public health crisis and is responsible for 30% of the global burden of
idiopathic intellectual disability, according to the World Health Organization (WHO). Exposure to lead during fetal
and early child development can have significant structural and functional effects on the brain and other organ
systems, and early symptoms of lead poisoning like neurological impairment and behavior disorders are hard to
identify. The CDC has declared that no level of Pb exposure is safe for children, yet the vast majority of newborns,
infants, and children in the US are not tested. A major limitation of current diagnostic testing for measuring blood
lead levels (BLL) is that it requires venous blood. Venipuncture is technically difficult to implement on infants,
and it is a frightening procedure for young children, which serve as an obstacle to Pb screening. This has led to
less than half of children under 6 years of age currently being tested for Pb exposures in the US. As a result,
there is a critical unmet need for new approaches to Pb screening in early life to identify at-risk individuals and
inform remediation efforts to remove or reduce Pb exposures during critical stages of human development. In
this Phase I STTR application we will optimize and validate a metals-free dried blood spot (DBS) collection
device to accurately quantify low BLLs in a single drop of capillary blood collected on filter paper. Our approach
features the following innovative and patented technology: (1) A process to remove Pb contamination from filter
paper before blood is collected, (2) A device to protect the filter paper from environmental Pb contamination
before, during, after blood collection, and (3) The use of discs of filter paper with known blood saturation volumes
to allow for accurately and precisely blood volume estimates, while simplifying blood extraction procedures in
the laboratory. Our approach combines the low cost and burden of capillary blood sampling with rigorous
quantification of BLLs in the lab. Successful completion of these study aims will result in a simple, low-cost, and
minimally-invasive blood collection device that can quantify BLLs with precision and detection limits similar to
gold standard venipuncture methods. This will provide new market opportunities to expand Pb testing in
newborn, infant, and children populations.

## Key facts

- **NIH application ID:** 10920930
- **Project number:** 1R41ES036480-01
- **Recipient organization:** SKYWAY BIOSCIENCES
- **Principal Investigator:** Punkaj Ahuja
- **Activity code:** R41 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $295,923
- **Award type:** 1
- **Project period:** 2024-09-11 → 2025-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10920930

## Citation

> US National Institutes of Health, RePORTER application 10920930, Optimization and Validation of Minimally-Invasive and Low-Cost Blood Collection Device for Lead Testing (1R41ES036480-01). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10920930. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*